Differences in real-world (RW) non-small cell lung cancer (NSCLC) treatment patterns among people living with HIV/AIDS (PLWHA) compared to those without HIV/AIDS (PWoHA). J Clin Oncol 2020: 38, no. 15_suppl, 7070-7070.
Perceptions of Community Hematologists/Oncologists on the Potential of Data Presented at ASH 2018 and ASCO 2019 to Alter the Standard of Care for Multiple Myeloma Treatment. Blood 2019: 134 (Supplement 1): 5822.
Gajra A, Sweat R, Jeune-Smith Y, Kish JK, Feinberg BA. Perceptions of Community Hematologists/Oncologists on Barriers to Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Diffuse Large B-Cell Lymphoma. Blood 2019: 134 (Supplement 1): 2198.
Real-world outcomes with multiple second-line treatments after first-line lenvatinib in patients with radioactive iodine refractory differentiated thyroid cancer (RAIR DTC). Thyroid. 2019:P-1-A-166, 388.
Chatterjee D, Kish J, Wang EC, Misir S, Myerscough C, Liassou D, Feinberg B.
Utilization and outcomes of eribulin mesylate Post a cyclin-dependent kinase 4/6 inhibitor: an observational real-world study in United States community oncology practices (EMPOWER). Ann Oncol 2019: 30 (Supplement 3), III54.
Mougalian SS, Wang E, Alexis K, Feinberg BA, Nero D, Miller T, Laney J, Chatterjee D, Knoth RL, Kish JK.
Real-world time to next treatment (TTNT) for first-line (1L) targeted and immuno-oncology therapies for BRAF-mutated metastatic melanoma (MM) by lactate dehydrogenase (LDH) level. J Clin Oncol 2019: 37, no. 8, 141-141.
Luke J, Ghate SR, Kish JK, Lee CH, Nidife B, McAllister L, Mehta S, Nakasato AR, Feinberg BA.
Treatment patterns in recurrent or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) post platinum-based therapy (PPBT) in the immuno-oncology (IO) era. Value in Health 2018: 21 (Supplement 3), S56.
Radtchenko J, Korytowsky B, Abraham P, Singh P, Feinberg BA.
Objective Response Rate (ORR) and Time to Treatment Failure (TTF) for BRAF v600 Mutated Metastatic Melanoma (BRAF+ MM) Patients Receiving First-Line (1L) Treatment with Dabrafenib/Trametinib (D+T) v Ipilimumab/Nivolumab (I+N) and Nivolumab or Pembrolizumab (N/P) Monotherapy at US-based Community Oncology Practices. J Clin Oncol 2018: 36, no. 15_suppl, e21538.
Feinberg BA, Kish J, Ghate S, Ndife B, Lee C, McAllister L, Mehta S, Nakasato A, Luke J.
Impact of human papillomavirus (HPV) etiology and immuno-oncology therapy (IO) availability on the patient journey in squamous cell carcinoma of the head and neck (SCCHN). Value in Health 2018: 21, Supplement 1, S137.
Korytowsky B, Radtchenko J, Abraham P, Klinefelter P, Shaw JW, Feinberg B.
Assessing Readiness of US Community Rheumatologists for Implementation of Medicare Access and CHIP Reauthorization Act (MACRA), Merit-Based Incentive Payment System (MIPS) and Alternative Patient Models (APMS). Value in Health 2018: 21, Supplement 1, S90.
Radtchenko J, Nabhan C, Jeune-Smith Y, Feinberg B.
Demographic, Payer, and Clinical Characteristics of Patients Receiving Bevacizumab (BEV) and Ranibizumab (RAN) for Treatment of Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME). Value in Health 2018: 21, Supplement 1, S243.